EGFR and lung adenocarcinoma: Overall, we first reported the cases of 2 lung adenocarcinoma patients harboring EGFR ex20ins mutations (p.S768_D770dupSVD and p.N771_P772insVal) who received furmonertinib as first-line treatment and achieved PFS times of 8.13 and 10.90 months, respectively.